Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-Glycoprotein by Investigating the Pharmacokinetics of the P-Glycoprotein Probe Substrate Dabigatran Etexilate in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Dabigatran etexilate (Primary) ; Tepotinib (Primary)
- Indications Adenocarcinoma; Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 16 Jul 2018 Planned End Date changed from 20 Jul 2018 to 6 Aug 2018.
- 16 Jul 2018 Planned primary completion date changed from 20 Jul 2018 to 6 Aug 2018.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.